Sugi Predict

Sugi Predict / Compounds / SCHEMBL3197101

SCHEMBL3197101

SCHEMBL3197101

CC(C)=C(OC(=O)C(C)C)c1c(-c2ccc(F)cc2)nn2cc(C(F)(F)F)ccc12

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 4/20 0.47
▸ KCNK3 O14649 2/20 0.34
▸ CSNK1D P48730 2/20 0.33
▸ CSNK1E P49674 2/20 0.33
▸ CSNK1A1 P48729 1/20 0.33
▸ NTRK1 P04629 1/20 0.33
▸ NTRK2 Q16620 1/20 0.33
▸ SRC P12931 1/20 0.33
▸ BRAF P15056 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ SCN9A Q15858 1/20 0.32
▸ DHODH Q02127 1/20 0.32
▸ PTGER4 P35408 1/20 0.31
▸ GPR139 Q6DWJ6 1/20 0.31
▸ PTGS2 P35354 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3208171 0.83 MAPK14 (0.55) MAPK14KCNK3CSNK1DCSNK1ECSNK1A1
SCHEMBL5378944 0.82 MAPK14 (0.58) MAPK14KCNK3CSNK1DCSNK1ECSNK1A1
SCHEMBL30944245 0.79 MAPK14 (0.55) MAPK14CSNK1DCSNK1ECSNK1A1NTRK1
SCHEMBL30944198 0.79 MAPK14 (0.59) MAPK14CSNK1DCSNK1ECSNK1A1SRC
SCHEMBL3209665 0.77 MAPK14 (0.53) MAPK14KCNK3CSNK1DCSNK1ECSNK1A1
SCHEMBL3209673 0.77 MAPK14 (0.53) MAPK14KCNK3CSNK1DCSNK1ECSNK1A1
SCHEMBL5875536 0.77 MAPK14 (0.55) MAPK14KCNK3CSNK1DCSNK1ECSNK1A1
SCHEMBL5382134 0.73 MAPK14 (0.50) MAPK14CSNK1DCSNK1ECSNK1A1SRC
SCHEMBL5382140 0.73 MAPK14 (0.50) MAPK14CSNK1DCSNK1ECSNK1A1SRC
SCHEMBL5364802 0.70 MAPK14 (0.66) MAPK14CSNK1DCSNK1ECSNK1A1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2010-02-11 — — US disclosed
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE MEDICINOVA, INC. 2009-12-24 — — US disclosed
US-7585875-B2 Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use AVIGEN, INC. (US) 2009-09-08 — — US disclosed
EP-2038279-A2 SUBSTITUTED PYRAZOLO [1,5- ALPHA] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE Avigen, Inc. (US) 2009-03-25 — — EP disclosed
US-20080070912-A1 Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use AVIGEN, INC. (US) 2008-03-20 — — US disclosed
WO-2007146087-A2 SUBSTITUTED PYRAZOLO [1,5-α] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2007-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE PNPO, PDXK, CYP3A5 MAPK14 1459/4885KCNK3 897/4885CSNK1D 2744/4885
US-20080070912-A1 Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use PNPO, PDXK, P2RX5 MAPK14 1712/4885KCNK3 882/4885CSNK1D 2009/4885
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE PNPO, PDXK, CYP3A5 MAPK14 1459/4885KCNK3 897/4885CSNK1D 2744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.